Vacunación frente a la neumonía adquirida en la comunidad del adultoactualización 2021 del posicionamiento del Grupo de Neumoexpertos en Prevención

  1. E. Redondo 1
  2. I. Rivero-Calle 2
  3. E. Mascarós 3
  4. J.E. Yuste 4
  5. M. Fernández-Prada 5
  6. D. Ocaña 6
  7. I. Jimeno 7
  8. A. Gilo 8
  9. J. Molina 9
  10. J.L. Díaz-Maroto 10
  11. M. Linares 11
  12. F. Martinón-Torres 2
  1. 1 Centro de Salud Internacional, Ayuntamiento de Madrid, Madrid, España
  2. 2 Hospital Clínico Universitario, Santiago de Compostela, A Coruña, España
  3. 3 Departamento de Salud Hospital la Fe, Consultorio Auxiliar Arquitecto Tolsá, Valencia, España
  4. 4 Instituto de Salud Carlos III y CIBER de Enfermedades Respiratorias (CIBERES), Madrid, España
  5. 5 Servicio Medicina Preventiva y Salud Pública, Hospital Vital Álvarez Buylla, Mieres, Asturias, España
  6. 6 Centro de Atención Primaria Algeciras-Norte, Algeciras, Cádiz, España
  7. 7 Centro de Salud Isla de Oza, Madrid, España
  8. 8 Medicina Preventiva y Salud Pública, Universidad Rey Juan Carlos, Madrid, España
  9. 9 Centro de Atención Primaria Francia, Fuenlabrada, Madrid, España
  10. 10 Centro de Atención Primaria de Guadalajara, Guadalajara, España
  11. 11 Microbiología clínica, Miembro del Grupo de Enfermedades Infecciosas de SEMERGEN. Fundación iO, España
Mostrar afiliacións +
Revista:
Semergen: revista española de medicina de familia

ISSN: 1138-3593

Ano de publicación: 2021

Número: 6

Páxinas: 411-425

Tipo: Artigo

DOI: 10.1016/J.SEMERG.2021.06.005 DIALNET GOOGLE SCHOLAR

Outras publicacións en: Semergen: revista española de medicina de familia

Resumo

La neumonía adquirida en la comunidad (NAC) continúa siendo una causa importante de morbimortalidad en adultos. El objetivo de este trabajo es actualizar la guía práctica de prevención de la NAC mediante vacunación en España desarrollada en 2016 y actualizada en 2018, en función de las vacunas y las evidencias disponibles mediante revisión bibliográfica y opinión de expertos. La llegada de la COVID-19 como nueva causa de NAC y la reciente aprobación y disponibilidad de cuatro vacunas seguras y eficaces constituyen el cambio más significativo. Las vacunas frente al neumococo, la gripe, la tosferina y la COVID-19 pueden contribuir a disminuir la carga de enfermedad por NAC y sus complicaciones asociadas. La evidencia disponible avala las indicaciones prioritarias establecidas en esta guía, y sería recomendable tratar de lograr una difusión e implementación amplia en la práctica clínica rutinaria de estas recomendaciones.

Referencias bibliográficas

  • E. Redondo, I. Rivero, D.A. Vargas, E. Mascarós, J.L. Díaz-Maroto, M. Linares, et al., en nombre de Neumoexpertos en Prevención Vacunación frente a la neumonía adquirida en la comunidad del adulto. Posicionamiento del Grupo de Neumoexpertos en Prevención [Vaccination against community acquired pneumonia in adult patients. A position paper by Neumoexpertos en Prevención] Semergen., 42 (2016), pp. 464-475, 10.1016/j.semerg.2016.07.009 PMID: 27641310 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • E. Redondo, I. Rivero-Calle, D.A. Vargas, E. Mascarós, J.L. Díaz-Maroto, M. Linares, et al., en nombre de Neumoexpertos en Prevención Vacunación frente a la neumonía adquirida en la comunidad del adulto. Actualización 2018 del posicionamiento del Grupo de Neumoexpertos en Prevención [Adult community acquired pneumonia vaccination: 2018 update of the positioning of the Pneumonia Prevention Expert Group] Semergen., 44 (2018), pp. 590-597, 10.1016/j.semerg.2018.09.005 PMID: 30318406 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • F.P. Polack, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine N Engl J Med. (2020), 10.1056/NEJMoa2034577 Google Scholar
  • M. Fernández-Prada, I. Rivero-Calle, A. Calvache-González, F. Martinón-Torres Acute onset supraclavicular lymphadenopathy coinciding with intramuscular mRNA vaccination against COVID-19 may be related to vaccine injection technique, Spain January and February 2021 Euro Surveill, 26 (2021), 10.2807/1560-7917.ES.2021.26.10.2100193 pii: 2100193 Google Scholar
  • S. Mallapaty Vaccines are curbing COVID: Data from Israel show drop in infections Nature, 590 (2021), p. 197, 10.1038/d41586-021-00316-4 View PDFCrossRefView Record in ScopusGoogle Scholar
  • M. Levine-Tiefenbrun, I. Yelin, R. Katz, E. Herzel, Z. Golan, L. Schreiber, et al. Decreased SARS-CoV-2 viral load following vaccination MedRxiv (2021), 10.1101/2021.02.06.21251283 Google Scholar
  • N. Dagan, N. Barda, E. Kepten, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting New Eng J Med (2021), 10.1056/NEJMoa2101765 Google Scholar
  • S. Amit, G. Regev-Yochay, A. Afek, et al. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients Lancet (2021), 10.1016/S0140-6736(21)00448-7 Google Scholar
  • Aran D. Estimating real-world COVID-19 vaccine effectiveness in Israel using aggregated counts. Disponible en: https://doi.org/10.1101/2021.02.05.21251139 Google Scholar
  • Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, et al. Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN Study). Disponible en: https://ssrn.com/abstract=3790399 Google Scholar
  • L.R. Baden, H.M. el Sahly, B. Essink, K. Kotloff, S. Frey, R. Novak, et al., COVE Study Group Efficacy and Safety of the mRNA-1273 SARS-CoV-2 vaccine N Engl J Med., 384 (2021), pp. 403-416, 10.1056/NEJMoa2035389 PMID: 33378609; PMCID: PMC7787219 View PDFCrossRefView Record in ScopusGoogle Scholar
  • M. Voysey, S.A.C. Clemens, S.A. Madhi, L.Y. Weckx, P.M. Folegatti, P.K. Aley, et al., Oxford COVID Vaccine Trial Group Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Lancet, 397 (2021), pp. 99-111, 10.1016/S0140-6736(20)32661-1 PMID: 33306989; PMCID: PMC7723445 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • M.N. Ramasamy, A.M. Minassian, K.J. Ewer, A.L. Flaxman, P.M. Folegatti, D.R. Owens, et al., Oxford COVID Vaccine Trial Group Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial Lancet., 396 (2021), pp. 1979-1993, 10.1016/S0140-6736(20)32466-1 PMID: 33220855; PMCID: PMC7674972 ArticleDownload PDFGoogle Scholar
  • Vasileiou E, Simpson CR, Robertson C, Shi T, Kerr S, et al. Effectiveness of First Dose of COVID-19 Vaccines Against Hospital Admissions in Scotland: National Prospective Cohort Study of 5.4 Million People. Disponible en: https://ssrn.com/abstract=3789264 Google Scholar
  • Hyams C, Marlow R, Maseko Z, King J, Ward L, Fox K, et al. Assessing the Effectiveness of BNT162b2 and ChAdOx1nCoV-19 COVID-19 Vaccination in Prevention of Hospitalisations in Elderly and Frail Adults: A Single Centre Test Negative Case-Control Study. Disponible en: https://ssrn.com/abstract=3796835, o https://doi.org/10.2139/ssrn.3796835 Google Scholar
  • Estrategia de vacunación frente a COVID 19 en España. Actualización 3. Grupo de Trabajo Técnico de Vacunación COVID-19, de la Ponencia de Programa y Registro de Vacunaciones. 9 de febrero de 2021. Disponible en https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/covid19/docs/COVID-19_Actualizacion3_EstrategiaVacunacion.pdf Google Scholar
  • GBD 2016 Lower Respiratory Infections Collaborators Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 Lancet Infect Dis., 18 (2018), pp. 1191-1210, 10.1016/S1473-3099(18)30310-4 PMID: 30243584 Google Scholar
  • J. Darbà, A. Marsà Hospital incidence, in-hospital mortality and medical costs of pneumococcal disease in Spain (2008-2017): A retrospective multicentre study Curr Med Res Opin (2021), 10.1080/03007995.2021.187600 Google Scholar
  • S. De Miguel, M. Domenech, F. González-Camacho, J. Sempere, D. Vicioso, J.C. Sanz, et al. Nationwide trends of invasive pneumococcal disease in Spain (2009-2019) in children and adults during the pneumococcal conjugate vaccine era Clin Infect Dis. (2020), 10.1093/cid/ciaa1483 PMID: 32990303 Google Scholar
  • D.M. Morens, J.K. Taubenberger, A.S. Fauci Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: Implications for pandemic influenza preparedness J Infect Dis., 198 (2008), pp. 962-970, 10.1086/591708 PMID: 18710327; PMCID: PMC2599911 View PDFCrossRefView Record in ScopusGoogle Scholar
  • E.Y. Klein, B. Monteforte, A. Gupta, W. Jiang, L. May, Y. Hsieh, et al. The frequency of influenza and bacterial coinfection: A systematic review and meta-analysis Influenza Other Respir Viruses., 10 (2016), pp. 394-403 View PDFCrossRefView Record in ScopusGoogle Scholar
  • D.M. Weinberger, K.P. Klugman, C.A. Steiner, L. Simonsen, C. Viboud Association between respiratory syncytial virus activity and pneumococcal disease in infants: A time series analysis of US hospitalization data PLoS Med., 12 (2015), p. e1001776, 10.1371/journal.pmed.1001776 PMID: 25562317; PMCID: PMC4285401 View PDFCrossRefGoogle Scholar
  • L.J. McGarry, K.E. Gilmore, J.L. Rubin, K.P. Klugman, D.R. Strutton, M.C. Weinstein Impact of 13-valent pneumococcal conjugate vaccine (PCV13) in a pandemic similar to the 2009 H1N1 in the United States BMC Infect Dis., 13 (2013), p. 229 View PDFView Record in ScopusGoogle Scholar
  • X. Zhu, Y. Ge, T. Wu, K. Zhao, Y. Chen, B. Wu, et al. Co-infection with respiratory pathogens among COVID-2019 cases Virus Res., 285 (2020), p. 198005, 10.1016/j.virusres.2020.198005 PMID: 32408156; PMCID: PMC7213959 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • D. Contou, A. Claudinon, O. Pajot, M. Micaëlo, P. Longuet Flandre, et al. Bacterial and viral co-infections in patients with severe SARS-CoV-2 pneumonia admitted to a French ICU Ann Intensive Care., 10 (2020), p. 119, 10.1186/s13613-020-00736-x PMID: 32894364; PMCID: PMC7475952 View PDFView Record in ScopusGoogle Scholar
  • M. Nieto-Moro, F.G. Ecclesia, I. Tomé-Masa, G. de Lama Caro-Patón, I. Leoz-Gordillo, et al. SARS-CoV-2 and Streptococcus pneumoniae coinfection as a cause of severe pneumonia in an infant Pediatr Pulmonol., 55 (2020), pp. 2198-2200, 10.1002/ppul.24916 PMID: 32602267; PMCID: PMC7361827 View PDFCrossRefView Record in ScopusGoogle Scholar
  • D. Cucchiari, J.M. Pericàs, J. Riera, R. Gumucio, E.C. Md, D. Nicolás Hospital Clínic 4H Team Pneumococcal superinfection in COVID-19 patients: A series of 5 cases Med Clin (Barc)., 155 (2020), pp. 502-505, 10.1016/j.medcli.2020.05.022 PMID: 32591180; PMCID: PMC7274636 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • J. Toombs, K. van der Abbeele, J. Democratis, A.K.J. Mandal, C.G. Missouris Pneumococcal co-infection in Covid-19 patients J Med Virol. (2020), 10.1002/jmv.26278 Google Scholar
  • C. Lai, C. Wang, P. Hsueh Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents? J Microbiol Immun Infect, 53 (2020), pp. 505-512 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • M. Noale, C. Trevisan, S. Maggi, R.A. Incalzi, C. Pedone, M. di Bari, et al. The association between influenza and pneumococcal vaccinations and SARS-CoV-2 infection: Data from the EPICOVID19. Web-based survey Vaccines, 8 (2020), p. 471 View PDFCrossRefGoogle Scholar
  • R. Root-Bernstein Age and location in severity of COVID-19 pathology: Do lactoferrin and pneumococcal vaccination explain low infant mortality and regional differences? Bioessays., 42 (2020), p. e2000076, 10.1002/bies.202000076 PMID: 32869330 Google Scholar
  • M.C. Nunes, C.L. Cutland, K.P. Klugman, S.A. Madhi Pneumococcal conjugate vaccine protection against coronavirus-associated pneumonia hospitalization in children living with and without HIV mBio., 12 (2021), p. e02347-20, 10.1128/mBio.02347-20 PMID: 33419872; PMCID: PMC7845626 Google Scholar
  • A. Matanock, G. Lee, R. Gierke, M. Kobayashi, A. Leidner, T. Pilishvili Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥ 65 years MMWR., 68 (2019), pp. 1069-1075 View PDFCrossRefView Record in ScopusGoogle Scholar
  • S. De Miguel, M. Domenech, F. González-Camacho, J. Sempere, D. Vicioso, J.C. Sanz, et al. Nationwide trends of invasive pneumococcal disease in spain from 2009 through 2019 in children and adults during the pneumococcal conjugate vaccine era Clin Infect Dis. (2020), 10.1093/cid/ciaa1483 Google Scholar
  • A. Cassini, E. Colzani, A. Pini, M,J.J. Mangen, D. Plass, S.A. McDonald, et al. Impact of infectious diseases on population health using incidence-based disability-adjusted life years (DALYs): Results from the Burden of Communicable Diseases in Europe study European Union and European Economic Area countries, 2009 to 2013 Eurosurveillance., 23 (2018), p. 17 View Record in ScopusGoogle Scholar
  • J.M. Rudd, H.K. Ashar, V.T. Chow, N. Teluguakula Lethal synergism between influenza and Streptococcus pneumoniae J Infect Pulm Dis., 2 (2016), 10.16966/2470-3176.114 Google Scholar
  • J.C. Kwong, K.L. Schwartz, M.A. Campitelli, H. Chung, N.S. Crowcroft, T. Karnauchow, et al. Acute myocardial infarction after laboratory-confirmed influenza infection N Engl J Med., 378 (2018), pp. 345-353 View Record in ScopusGoogle Scholar
  • V. Sender, K. Hentrich, A. Pathak, A.T.Q. Ler, B.T. Embaie, S.L. Lundström, et al. Capillary leakage provides nutrients and antioxidants for rapid pneumococcal proliferation in influenza-infected lower airways Proc Natl Acad Sci., 117 (2020), pp. 31386-31397 View PDFCrossRefView Record in ScopusGoogle Scholar
  • A.E. Merkler, N.S. Parikh, S. Mir, A. Gupta, H. Kamel, E. Lin, et al. Risk of ischemic stroke in patients with coronavirus disease 2019 (COVID-19) vs patients with influenza JAMA Neurol (2020), 10.1001/jamaneurol.2020.2730 Google Scholar
  • D.M. Musher, M.S. Abers, V.F. Corrales-Medina Acute infection and myocardial infarction N Engl J Med., 380 (2019), pp. 171-176, 10.1056/NEJMra1808137 PMID: 3062506 View PDFCrossRefView Record in ScopusGoogle Scholar
  • M.D. Nowak, E.M. Sordillo, M.R. Gitman, A.E. Paniz Mondolfi Coinfection in SARS-CoV-2 infected patients: Where are influenza virus and rhinovirus/enterovirus? J Med Virol., 92 (2020), pp. 1699-1700, 10.1002/jmv.25953 PMID: 32352574; PMCID: PMC7267652 View PDFCrossRefView Record in ScopusGoogle Scholar
  • C. Zanettini, M. Omar, W. Dinalankara, E.L. Imada, E. Colantuoni, G. Parmigiani, et al. Influenza vaccination and COVID19 mortality in the USA medRxiv, 26 (2020), p. 2020, 10.1101/2020.06.24.20129817 PMID: 32607525; PMCID: PMC7325191 Google Scholar
  • G. Fink, N. Orlova-Fink, T. Schindler, S. Grisi, A.P.S. Ferrer, C. Daubenberger, et al. Inactivated trivalent influenza vaccination is associated with lower mortality among patients with COVID-19 in Brazil BMJ Evid Based Med. (2020), 10.1136/bmjebm-2020-111549 PMID: 33310766; PMCID: PMC7735072 Google Scholar
  • J. Stowe, E. Tessier, H. Zhao, et al. Interactions between SARS-CoV-2 and influenza and the impact of coinfection on disease severity: a test negative design medRxiv (2020) https://www.medrxiv.org/content/10.1101/2020.09.18.20189647v1.full.pdf Google Scholar
  • A. Aidoud, J. Marlet, D. Angoulvant, C. Debacq, G. Gavazzi, B. Fougère Influenza vaccination as a novel means of preventing coronary heart disease: Effectiveness in older adults Vaccine (2020), 10.1016/j.vaccine.2020.05.070 Google Scholar
  • A. Sen, I.J. Bakken, R.E.S. Govatsmark, T. Varmdal, K.H. Bønaa, K.J. Mukamal, et al. Influenza vaccination and risk for cardiovascular events: A nationwide self-controlled case series study BMC Cardiovasc Disord, 21 (2021), pp. 1-11 View PDFCrossRefView Record in ScopusGoogle Scholar
  • A. Garcia, R. Ortiz de Lejarazu, J. Reina, D. Callejo, J. Cuervo, R. Morano Larragueta Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain Hum Vaccin Immunother., 12 (2016), pp. 2269-2277 View PDFCrossRefView Record in ScopusGoogle Scholar
  • V.C. Huber Influenza vaccines: From whole virus preparations to recombinant protein technology Expert Rev Vaccines., 13 (2014), pp. 31-42 View PDFCrossRefView Record in ScopusGoogle Scholar
  • R. Ortiz de Lejarazu, S. Tamames [Influenza vaccination Effectiveness of current vaccines and future challenges] Enferm Infec Microbiol Clin., 33 (2015), pp. 480-490 ArticleDownload PDFGoogle Scholar
  • P.C. Soema, R. Kompier, J.P. Amorij, G.F.A. Kersten Current and next generation influenza vaccines: Formulation and production strategies Eur J Pharm Biopharm., 94 (2015), pp. 251-263 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • P.K. Tosh, R.M. Jacobson, G.A. Poland Influenza vaccines: From surveillance through production to protection Mayo Clinic Proc., 85 (2010), pp. 257-273 ArticleDownload PDFCrossRefView Record in ScopusGoogle Scholar
  • S.S. Wong, R.J. Webby Traditional and new influenza vaccines Clin Microbiol Rev., 26 (2013), pp. 476-492 View PDFView Record in ScopusGoogle Scholar
  • A. Perez-Rubio, J.M. Eiros Bouza Cell culture-derived flu vaccine: Present and future Hum Vaccin Immunother., 14 (2018), pp. 1874-1882 View PDFCrossRefGoogle Scholar
  • A. Gil de Miguel, E. Redondo Marguello, J. Díez Domingo, R. Ortiz de Lejarazu, F. Martinón Torres Vacuna antigripal trivalente de alta dosis. Eficacia y efectividad [High-dose trivalent influenza vaccine. Efficacy and effectiveness] Rev Esp Quimioter., 33 (2020), pp. 226-239 View PDFCrossRefGoogle Scholar
  • R. Ortiz de Lejarazu, F. Martinón Torres, A. Gil de Miguel, J. Díez Domingo, E. Redondo Marguello Vacuna antigripal trivalente de alta dosis: seguridad e inmunogenicidad [High-dose trivalent influenza vaccine: Safety and immunogenicity] Rev Esp Quimioter., 34 (2021), pp. 1-11 View PDFCrossRefView Record in ScopusGoogle Scholar
  • A. Chit, D.L. Becker, C.A. Diaz Granados, M. Maschio, E. Yau, M. Drummond Cost-effectiveness of high-dose versus standard-dose inactivated influenza vaccine in adults aged 65 years and older: An economic evaluation of data from a randomised controlled trial Lancet Infect Dis., 15 (2015), pp. 1459-1466 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • D.L. Becker High-dose inactivated influenza vaccine is associated with cost savings and better outcomes compared to standard-dose inactivated influenza vaccine in Canadian seniors Hum Vaccin Immunother., 12 (2016), pp. 3036-3042 View PDFCrossRefView Record in ScopusGoogle Scholar
  • T.I. Shireman, J. Ogarek, P. Gozalo, et al. Cost benefit of high-dose vs standard-dose influenza vaccine in a long-term care population during an A/H1N1-predominant influenza season J Am Med Dir Assoc., 20 (2019), pp. 874-878 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • R. Van Aalst, E. Russo, N. Neupane, et al. Economic assessment of a high-dose versus standard-dose influenza vaccine: Estimating the impact on hospitalization cost for cardio-respiratory disease in the US veteran population Paper presented at: ISPOR; 18-22 May (2019) New Orleans, LA, USA Google Scholar
  • A. Chit, J. Roiz, B. Briquet, D.P. Greenberg Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors Vaccine., 33 (2015), pp. 734-741 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • L. Skinner, J. Jacob, F. Bianic, et al. An economic model to estimate the cost-effectiveness of trivalent influenza vaccine high dose for the elderly population in England and Wales Paper presented at: International Society for Pharmacoeconomics Outcomes Research (ISPOR) 21st Annual European Conference; November 10-14 (2018) Barcelona, Spain Google Scholar
  • N. Largeron, A. Manton, P. Net, et al. An economic model to estimate the public health impact and cost-effectiveness of vaccination of seniors with Fluzone high dose influenza vaccine in Australia Paper presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 8th Asia Pacific Conference; September 8-11 (2018) Tokyo, Japan Google Scholar
  • J.M.S.K Raviotta, J. DePasse, et al. Cost-effectiveness and public health effect of influenza vaccine strategies for US elderly adults J Am Geriatr Soc., 64 (2016), pp. 2126-2131 View PDFCrossRefView Record in ScopusGoogle Scholar
  • P. Crépey, L. Skinner, S. Carroll, et al. A dynamic transmission model to estimate the public health impact and cost-effectiveness of trivalent influenza vaccine high dose for the elderly population in England and Wales (November 10-14, 2018) Barcelona, Spain
  • Consultado 29 Mar 2021. Disponible en: https://www.ema.europa.eu/en/documents/product-information/supemtek-epar-product-information_en.pdf Google Scholar
  • C.I. Paules, S.G. Sullivan, K. Subbarao, A.S. Fauci Chasing seasonal influenza — The need for a universal influenza vaccine N Engl J Med., 378 (2018), pp. 7-9 View PDFCrossRefView Record in ScopusGoogle Scholar
  • V.A. Jenkins, M. Savi, W. Kandeil Pertussis in high-risk groups: An overview of the past quarte-century Hum Vaccin Immunother., 16 (2020), pp. 2609-2617 View PDFCrossRefView Record in ScopusGoogle Scholar
  • European Centre for Disease Prevention and Control Pertussis ECDC Annual Epidemiological Report for 2018, ECDC, Stockholm (2020) [consultado 29 Mar 2021. Disponible en: https://www.ecdc.europa.eu/sites/default/files/documents/AER_for_2018_pertussis.pdf Google Scholar
  • R. Weinberger, M. Riffelman, N. Kennerknecht, C. Hülbe, M. Littmann, J. O’Brien, et al. Long-lasting cough in an adult German population: Incidence, symptoms, and related pathogens Eur J Clin Microbiol Infec Dis., 37 (2018), pp. 665-672 View PDFCrossRefView Record in ScopusGoogle Scholar
  • W. Kandeil, P. Atanasov, D. Avramioti, J. Fu, N. Demarteau, X. Li The burden of pertussis in older adults: What is the role of vaccination? Asystematic literatura review Exp Rev Vaccines., 18 (2019), pp. 439-455 View PDFCrossRefView Record in ScopusGoogle Scholar
  • M. Campins, D. Moreno-Pérez, A. Gil-de Miguel, F. González-Romo, F.A. Moraga-Llop, J. Arístegui-Fernández, et al. Tos ferina en España. Situación epidemiológica y estrategias de prevención y control. Recomendaciones del Grupo de Trabajo de Tos ferina Enferm Infecc Microbiol Clin., 31 (2013), pp. 240-253, 10.1016/j.eimc.2012.12.011 PMID: 23411362 ArticleDownload PDFView Record in ScopusGoogle Scholar
  • F. Moraga, M. Campins Vacuna de la tos ferina. Reemergencia de la enfermedad y nuevas estrategias de vacunación Enferm Infecc Microbiol Clin., 33 (2015), pp. 190-196 Google Scholar
  • S.J. Olsen, E. Azziz-Baumgartner, A.P. Budd, et al. Decreased influenza activity during the COVID-19 pandemic — United States, Australia Chile, and South Africa, 2020 MMWR Morb Mortal Wkly Rep, 69 (2020), pp. 1305-1309, 10.15585/mmwr.mm6937a6 View PDFCrossRefView Record in ScopusGoogle Scholar
  • H. Sakamoto, M. Ishikane, P. Ueda Seasonal influenza activity during the SARS-CoV-2 outbreak in Japan JAMA., 323 (2020), pp. 1969-1971, 10.1001/jama.2020.6173
Fonte de datos: Dialnet